Tyra Biosciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the fiscal quarter and nine months ended September 30, 2026, disclosing a net loss of $135.985 million for the nine-month period and reporting total assets of $727.526 million as of September 30, 2026.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $135.985 million for the nine months ended September 30, 2026, compared to $86.113 million in the same period of 2025.
  • Third-quarter net loss: Net loss for the three months ended September 30, 2026 was $51.122 million, versus $29.868 million in the prior-year quarter.
  • Equity offering in Q3 2026: The company issued 9,079,000 shares of common stock and pre-funded warrants, net of issuance costs, adding $376.174 million to stockholders' equity, per the condensed statements of stockholders' equity.
  • Total assets: Total assets were $727.526 million at September 30, 2026, up from $282.609 million at December 31, 2025.
  • Cash and cash equivalents: Cash and cash equivalents increased to $456.016 million at September 30, 2026, from $77.387 million at December 31, 2025.
  • Shares outstanding: As of November 6, 2026, the registrant had 69,082,747 shares of common stock outstanding.
  • Operating expenses: Total operating expenses for the nine months ended September 30, 2026 were $145.887 million, including $115.812 million in research and development and $30.075 million in general and administrative costs.

Tyra Biosciences Financial Position and Operations Through September 2026

Tyra Biosciences, Inc., a clinical-stage biosciences company incorporated in Delaware and headquartered in Carlsbad, California, filed its quarterly report on NASDAQ:TYRA for the period ended September 30, 2026. According to the filing, total operating expenses rose to $145.887 million for the nine months ended September 30, 2026, from $96.246 million in the same period a year earlier. Research and development expenses were the primary driver, reaching $115.812 million for the nine-month period, compared to $74.742 million in the prior-year period, reflecting ongoing clinical and preclinical programs.

The company disclosed net interest and other income of $9.902 million for the nine months ended September 30, 2026, partially offsetting operating losses. The net loss per share, basic and diluted, was $(2.07) for the nine months ended September 30, 2026, based on weighted-average shares of 65,633,506. For the third quarter alone, net loss per share was $(0.74), based on weighted-average shares of 69,082,673.

According to the condensed statements of stockholders' equity, during the third quarter of 2026, the company issued 9,079,000 shares of common stock and pre-funded warrants, net of issuance costs, which the filing records as adding $376.174 million to additional paid-in capital. Additionally, during the first quarter of 2026, the company issued 4,690,532 shares under an at-the-market offering program, net of issuance costs, contributing $147.853 million. The accumulated deficit stood at $507.243 million as of September 30, 2026, compared to $371.258 million at December 31, 2025. Total stockholders' equity was $692.844 million at the end of the reporting period. The company also reported stock-based compensation of $30.235 million for the nine months ended September 30, 2026.

What Was Disclosed

Tyra Biosciences disclosed its unaudited financial results for the quarter and nine months ended September 30, 2026, including a $135.985 million nine-month net loss, a significant increase in total assets to $727.526 million, and equity raised through common stock and pre-funded warrant issuances during the period.